About MayMag Biologics

Redefining Sterile Pharmaceutical Manufacturing

We are a 506(e)-registered, FDA-compliant industrial biologics manufacturer headquartered in Dallas, Texas — built to solve the world's most critical drug shortage challenges at scale.

Our Mission

To manufacture and distribute high-quality, affordable sterile biologics and biosimilar drugs that address global shortages — with uncompromising compliance, precision, and speed.

Our Story

MayMag Biologics was founded with a singular purpose: to bridge the gap between global demand for life-saving injectable drugs and the manufacturing capacity needed to meet it. Originally operating as Tirzepatide Pharm Corp (dba Zeptide Pharma), we rebranded as MayMag Biologics to reflect our expanded scope and end-to-end sterile manufacturing capabilities.

From our FDA-registered, cGMP-compliant facility in Dallas, Texas, we manufacture insulin analogs, GLP-1/GIP receptor agonists, biosimilar diabetic drugs, sterile glaucoma medications, and a growing portfolio of balance and wellness injectables — all under 506(e) industrial outsourcing designation.

We do not serve retail 503B hospital and clinic compounding markets. Our focus is large-scale industrial production for pharmaceutical distributors, private-label partners, and global healthcare supply chains.

MayMag Biologics sterile manufacturing facility

Regulatory Credentials

FDA 506(e) Registration

Registered industrial outsourcing facility under the Drug Quality and Security Act (DQSA)

cGMP Compliance

Full compliance with 21 CFR Parts 210–211 current Good Manufacturing Practice regulations

GMP Certificate of Compliance

Certificate No. INGM/AN-27354/130977/0626 issued by UAMLS — covering Insulin Analogs, GLP-1s, Injectable Biologics, 503B & 506E Sterile Drugs, and Clinical IND

ISO 13485 Certified

Quality management system certified to ISO 13485 for medical device and pharmaceutical manufacturing

USP Chapter 797 Compliant

Sterile compounding operations meet USP 797 standards for pharmaceutical compounding

USP Chapter 800 Compliant

Hazardous drug handling meets USP 800 standards for personnel and environmental safety

What Drives Us

Compliance First

Every batch, every process, every decision is anchored in regulatory rigor. We treat compliance not as a checkbox but as the foundation of patient safety.

Scientific Precision

Our formulation scientists and manufacturing engineers apply exacting standards to every product — from API sourcing through sterile fill-finish and final release.

Global Impact

We manufacture at scale to address FDA drug shortage lists and supply pharmaceutical distributors across North America, Europe, and emerging markets.

Partner-Centric

We operate as a true manufacturing partner — transparent, responsive, and committed to long-term supply reliability for every client we serve.

Ready to Partner with Us?

Whether you need private-label manufacturing, bulk API supply, or a reliable 506(e) production partner, we want to hear from you.

Contact Our Team
MayMag Biologics

MayMag Biologics is a 506e industrial sterile pharma company that excels in large-scale manufacturing of FDA shortlist drugs for global distribution. FDA-registered biologics manufacturer. Does not provide retail 503B services to hospitals and clinics.

Contact

© MayMag Biologics (formerly Tirzepatide Pharma). USA Approved Biologics Manufacturer. FDA priority review · FDA accelerated approval pipeline · cGMP-certified · FDA-approved facility commercial manufacturing.